• F Wallet, D Maucort Boulch, S Malfroy, S Ledochowski, C Bernet, V Kepenekian, G Passot, O Vassal, V Piriou, O Glehen, and A Friggeri.
• Critical Care and Anaesthesiology Department, CHU Lyon Sud, University Lyon 1, Pierre Benite, France; Laboratoire des Pathogènes Emergents, Centre International de Recherche en Infectiologie, Inserm U1111, CNRS UMR5308, ENS de Lyon, UCBL1, France. Electronic address: florent.wallet@chu-lyon.fr.
• Eur J Surg Oncol. 2016 Jun 1; 42 (6): 855-60.

BackgroundCytoreductive surgery (CRS) and Hyperthermic intraperitoneal chemotherapy (HIPEC) are promising new approaches of peritoneal metastases. However these surgical procedures are associated with a high morbidity rate thus intensive care (IC) management following serious complications may be warranted for these patients. The impact of the prolonged IC stay or re-admission on long-term survival remains unknown.MethodsWe retrospectively analysed 122 consecutive HIPEC procedures over a one year period (2010-2011) in a single academic hospital. We analysed complications that would lead to prolonged stay or re-admission into ICU and analysed long term follow-up in patients whether they required intensive care (ICU group) or not (Control group).ResultsICU group represented 26.2% of the cohort mainly due to septic or haemorrhagic shock. Among them acute kidney injury and respiratory failure were present in 50% and 47% respectively. Cohort overall mortality rate was of 5.7%. Patients were followed for 4 years and survival analysis was performed adjusting for main confounding factors in a Cox survival model. Survival was not different between groups, with a median survival of 38 months [32; 44] vs. 33 months [26; 39] in the ICU group and Control group respectively.ConclusionProlonged stay or re-admission into ICU does not seem to statistically impact long term prognosis of patients undergoing CRS with HIPEC.Copyright © 2016 Elsevier Ltd. All rights reserved.

20 keywords...

hide…